Madrigal Pharmaceuticals, Inc. (MDGL)
Here's Why Madrigal (MDGL) is a Great Momentum Stock to Buy
Does Madrigal (MDGL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion
Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval, positioning it as a foundational therapy for NASH with advanced fibrosis. Broad insurance coverage and allowance for non-invasive testing [NIT] enhance patient accessibility and Rezdiffra's adoption rate. Competition from Novo Nordisk's Semaglutide poses a market risk, but Rezdiffra's liver-specific mechanism offers a targeted advantage.
Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up
MDGL stock is up as the company reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates
Madrigal (MDGL) came out with a quarterly loss of $4.92 per share versus the Zacks Consensus Estimate of a loss of $6.94. This compares to loss of $5.34 per share a year ago.
Madrigal Pharmaceuticals: Looking To Finally Establish A Position Around The Q3 Earnings
Madrigal Pharmaceuticals' Rezdiffra, approved for NASH, shows strong early demand and revenue growth, making Q3 earnings a potential catalyst for stock movement. Despite steep Q2 losses, Madrigal's $1.1B cash reserves and strategic execution position Rezdiffra as the market leader in NASH/MASH. Analysts forecast substantial revenue growth and narrowing losses for Madrigal, with expectations of profitability within a few years.
Why Is Madrigal (MDGL) Up 1% Since Last Earnings Report?
Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock?
Is Madrigal Pharmaceuticals Stock a Buy?
Madrigal Pharmaceuticals earned the first approval for a medicine in an area with a high unmet need. The biotech has more to do to dominate this market, considering it should become more crowded soon.
This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock
Novo Nordisk just canceled one of its early-stage clinical programs. Madrigal Pharmaceuticals is a specialist developer for the same target illness.
While Madrigal's Rezdiffra Impresses, Great Uncertainties Loom In MASH Market
Madrigal Pharmaceuticals' Q2 2024 revenue from Rezdiffra exceeded expectations at $14.6 million. The company's SG&A expenses surged to $105.4 million, reflecting launch activities. Over 2,000 patients are currently on Rezdiffra, with broad insurance coverage.
Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line
Madrigal (MDGL) posts better than expected second-quarter numbers. It adds nearly $15 million from sales of the first-ever NASH drug Rezdiffra, which is encouraging for a drug launched in April 2024.
Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2024 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Q2 2024 Results Conference Call August 7, 2024 8:00 AM ET Company Participants Tina Ventura - Chief Investor Relations Officer Bill Sibold - CEO, President & Director Mardi Dier - CFO & Senior VP Conference Call Participants Thomas Smith - Leerink Partners Andrea Tan - Goldman Sachs Andy Chen - Wolfe Research Eliana Merle - UBS Yasmeen Rahimi - Piper Sandler Ritu Baral - TD Cowen David Lebowitz - Citi Jon Wolleben - Citizens JMP Operator Good day, and thank you for standing by. Welcome to the Madrigal Pharmaceuticals Second Quarter 2024 Earnings Conference Call.
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates
Madrigal (MDGL) came out with a quarterly loss of $7.10 per share versus the Zacks Consensus Estimate of a loss of $7.55. This compares to loss of $4.69 per share a year ago.
